Real-world study of adebrelimab for advanced small cell lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This study is testing a drug called adebrelimab for people with advanced small cell lung cancer. It collects real-world information on how well the treatment works and how it affects patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of extensive-stage small cell lung cancer (cancer that has spread beyond the lung).
- You must be 18 years old or older.
- Your doctor must decide that adebrelimab treatment is right for you.
- You cannot be pregnant or breastfeeding.
- You must not be currently in another study where you don't know what treatment you're getting.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests immunotherapy drugs for extensive stage small cell lung cancer that has progressed after initial (first-line) chemotherapy. You may be eligible if you have finished standard treatment and your cancer has worsened.
This early-phase trial tests a new combination of drugs (HS-20093 plus other treatments) for people with extensive-stage small cell lung cancer whose cancer has not grown after their first round of treatment. The goal is to see if this new approach can keep the cancer from coming back.
This study looks at how well adebrelimab works and how safe it is in real-world settings for people with advanced small cell lung cancer that has spread. It may help doctors understand if this treatment is a good option for patients like you.
This trial tests adding the immunotherapy drug adebrelimab to standard chemotherapy and radiation to see if it works better than chemotherapy alone for people newly diagnosed with extensive-stage small cell lung cancer.
This study tests a drug called adebrelimab, used alone or with other treatments, for people with advanced solid tumors, including extensive-stage small cell lung cancer. It aims to see if adding this drug helps control the cancer.
This trial tests a combination of an immunotherapy drug (adebrelimab) plus chemotherapy and radiation therapy to see if it works better than standard treatment for people with extensive-stage small cell lung cancer who have not been treated before.
Hear when a new Extensive-stage Small Cell Lung Cancer (ES-SCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.